J. Vigne, J. Alexandre, F. Fobe
Jan 28, 2015
Citations
0
Influential Citations
12
Citations
Quality indicators
Journal
European Journal of Clinical Pharmacology
Abstract
Hydroxyzine is a first-generation antihistamine, antagonist of central and peripheral H1 receptors with anticholinergic properties. Marketed in France under the name Atarax®, it has been approved in the treatment of chronic urticaria, mild forms of anxiety, second-line therapy of insomnia in the child up to 6-year-old, and in premedication prior to general anesthesia. We report a severe QT prolongation exposing to risks of torsades de pointe (TdP) and sudden cardiac death during a per os medication at high posology with hydroxyzine.